As it focuses on longer-term growth opportunities, cancer screening test maker Exact Sciences Corp. is pausing on previous plans to build a new research and development facility in Madison, according to the company.

The company still intends to fulfill its commitment to create 1,300 Wisconsin jobs and invest $350 million in its facilities by 2025, Exact Sciences director of corporate communications Stephanie Spanos said via email on Feb. 3.

Exact Sciences (Nasdaq: EXAS), which is known for its at-home colorectal cancer screening test Cologuard, has been focused on reaching profitability. It laid off at least 580 employees in 2022, citing economic factors and the reprioritization of programs.

Click here to read the full article.